. 2015 May 15;10(5):e0126644. doi: 10.1371/journal.pone.0126644

Table 1. Differences in two rapamycin studies.

C57BL/6 responses to rapamycin 14ppm
Measure	Young-fed		Old-fed
	Female	Male	Female	Male
Fat-free mass	↓^***	↓^*** ^§	---	↓^* ^§
Total body mass	↑^*** ^§	↓^*** ^§	---	↑↓^*** ^§
Percent fat	↑^*** ^§	↓^*** ^§	---	---
Mass-specific Food Consumption	---	↑^** ^§	↓^**	---
Light phase O₂ consumption	---	---	↓^*	---
Dark phase O₂ consumption	↑^**	---	---	---
Resting Metabolic Rate	↑^*	↓^*** ^§	↓^**	---
Total activity (24h)	---	---	---	---
Total sleep	↑^*	↑^*	---	---
Sleep fragmentation	↓^**	↓^**	---	↓^**
Grip strength	↑^**	---	---	---
Rotarod performance	---	↓	↑^*	↑^*
Stride length	---	---	↑↓^**	↑↓^**
Survival	↑^**	↑^*	↑^**	↑^**

↑ Increased ↓ Decreased, ↑↓ Maintained with age,—No difference from controls

*p < 0.05

** p < 0.01

*** p < 0.001

^§ Treatment X Age effect

Healthspan measures: young-fed measured between ages 16 and 29 months; old-fed measured at 25, 31 and 32 months.

Young-fed mice (rapamycin feeding begun at 4 mo, this study) compared with old-fed (rapamycin feeding begun at 19 mo) [11].